within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB07_InterferonBeta1a;

model InterferonBeta1a
  extends Pharmacolibrary.Drugs.ATC.L.L03AB07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>InterferonBeta1a</td></tr><tr><td>ATC code:</td><td>L03AB07</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Interferon beta-1a is a recombinant form of human interferon beta, used primarily in the treatment of relapsing forms of multiple sclerosis (MS). It is approved by regulatory agencies such as the FDA and EMA for MS to reduce frequency of relapses and slow progression of physical disability.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy volunteers and MS patients after single subcutaneous or intramuscular administration.</p><h4>References</h4><ol><li><p>David, OJ, et al., &amp; Schmouder, RL (2012). Clinical pharmacokinetics of fingolimod. <i>Clinical pharmacokinetics</i> 51(1) 15–28. DOI:<a href=\"https://doi.org/10.2165/11596550-000000000-00000\">10.2165/11596550-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22149256/\">https://pubmed.ncbi.nlm.nih.gov/22149256</a></p></li><li><p>Saida, T, et al., &amp; Hao, Q (2012). Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions. <i>Multiple sclerosis (Houndmills, Basingstoke, England)</i> 18(12) 1782–1790. DOI:<a href=\"https://doi.org/10.1177/1352458512442261\">10.1177/1352458512442261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22492130/\">https://pubmed.ncbi.nlm.nih.gov/22492130</a></p></li><li><p>Rogge, MC, et al., &amp; Galluppi, GR (2014). Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent. <i>Journal of clinical pharmacology</i> 54(10) 1153–1161. DOI:<a href=\"https://doi.org/10.1002/jcph.311\">10.1002/jcph.311</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24737408/\">https://pubmed.ncbi.nlm.nih.gov/24737408</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end InterferonBeta1a;
